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0735-6757/© 2016 The Authors. Published by Elsevier IncDirect oral anticoagulants (DOACs) are a relatively recent addition to the oral anticoagulant armamentarium, and
provide an alternative to the use of vitamin K antagonists such as warfarin. Regardless of the type of agent used,
bleeding is the major complication of anticoagulant therapy. The decision to restart oral anticoagulation follow-
ing amajor hemorrhage in a previously anticoagulated patient is supported largely by retrospective studies rath-
er than randomized clinical trials (mostly with vitamin K antagonists), and remains an issue of individualized
clinical assessment: the patient’s risk of thromboembolism must be balanced with the risk of recurrent major
bleeding. This review provides guidance for clinicians regarding if and when a patient should be re-initiated on
DOAC therapy following a major hemorrhage, based on the existing evidence.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).The incidence rates of atrial ﬁbrillation (AF) in North America were
estimated at 264 per 100,000 person-years for men and 196 per
100,000 person-years for women in 2010 [1], and approximately 76
million prescriptions for oral anticoagulant (OAC) therapy for all indica-
tions were dispensed in the United States during 2013 [2]. Yet OACs are
underused in many patients with AF, and an elevated risk of stroke [3],
contrary to the recommendations of multiple current guidelines [4-6],
with rates of OAC prescribing in appropriately risk-stratiﬁed patients
ranging from 40% to 60% [7,8]. The most common complication of OAC
therapy is gastrointestinal (GI) bleeding, but the main cause of
bleeding-related morbidity and mortality is intracranial hemorrhage
(ICH) [9-11]. Physicians consistently underestimate the risk of stroke
in patients with AF and overestimate the risk of hemorrhage with OAC
therapy, leading to undertreatment, despite evidence of the beneﬁts of
OACs [8,12]. This bias is exacerbated once a patient suffers a majorngelheim Pharmaceuticals, Inc
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. This is an open access article underhemorrhage while receiving OAC therapy, particularly for clinicians in-
volved in the acute care of these episodes, as the bleeding is apparent
and dramatic, while the stroke that may be prevented by OAC therapy
is not. Although often counterintuitive, restarting OACs after OAC-
associated major hemorrhage is usually appropriate; however, the
main issue concerns the timing of the restart. Evidencebased data
from prospective, randomized, controlled clinical trials to address this
question are needed, particularly in direct OAC (DOAC)-treated patients
but are unavailable at present.
There are multiple deﬁnitions for assessing the severity of bleeding
episodes. Major hemorrhage is deﬁned by the International Society on
Thrombosis andHaemostasis as fatal bleeding, or symptomatic bleeding
in a critical area or organ, or bleeding causing a fall in hemoglobin level
of 20 g/L (1.24mmol/L or 2 g/dL) ormore, or leading to transfusion of ≥2
units of whole blood or red cells [13]. Consequently, patients enrolled
into studies of OAC-associated International Society on Thrombosis
and Haemostasis-deﬁned major bleeding consist of a heterogeneous
population arising from different clinical specialties, which compounds
the difﬁculties of studying these scenarios. Estimates of the risk ofmajor
hemorrhage related to OAC range from 2% to 3% in clinical trials to ap-
proximately 1% to 7% in population cohort studies [10,11,14]. The
exact incidence of major hemorrhage is unknown because of uncertain-
ty regarding the intensity of OAC therapy, and patient-related factors
such as history of bleeding, concomitant disease, alcohol use, age, and
risk of falls [10]. Regarding types of major hemorrhage related to OAC,
the largest amount of published data is for ICH and GI bleeding, and
this review will focus on these 2 clinical entities. Recommendations
for restarting OAC therapy in other major bleeding situations, which
are relatively rare, will remain as risk–beneﬁt decisions for the individ-
ual clinician and patient.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure. Unmatched survival and event rates in atrial ﬁbrillation patients: analyzing oral
anticoagulant resumption status. (Reproduced with permission from reference [27])
Unmatched Kaplan-Meier survival curves, ischemic, and hemorrhagic event rates in
atrial ﬁbrillation (AF) patients with and without oral anticoagulant (OAC) resumption.
(A) Kaplan-Meier survival rates of patients with AF with and without OAC resumption
from index-intracranial hemorrhage (ICH) until 1-year follow-up, analyzed by log-rank,
Breslow, and Tarone–Ware testing, with corresponding P values. (B) Incidence rates of
new ischemic events over the 1-year follow-up period in patients with and without OAC
resumption. (C) Incidence rates of hemorrhagic events over the 1-year follow-up period
in patients with and without OAC resumption. Numbers for patients at risk apply to
parts A–C. One year after OAC-related ICH 8.2% (n = 9/110) of resumed patients vs
37.5% (n = 171/456) of patients without OAC resumption had died (P b .001). The
crude incidence of bleeding events was not signiﬁcantly different among AF patients
with and without OAC resumption (OAC resumed: 7.3% [n = 8/110] vs 5.7% [n = 26/
456] nonresumed patients; P = .532), the incidence of new ischemic events was
signiﬁcantly increased in patients without OAC resumption (5.4% [n = 6/110] vs 14.9%
[n = 68/456]; P= .008).
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(VKAs), typically warfarin in the United States, although other VKAs
(eg, phenprocoumon and acenocoumarol) are used in other geographi-
cal areas. VKAs act by blocking vitamin K epoxide reductase to inhibit
the activation of clotting factors (F) II, VII, IX, and X, and natural antico-
agulant proteins C and S. However, in recent years, small-molecule
DOACs have become available, the ﬁrst of which was the direct throm-
bin inhibitor, dabigatran, which gained U.S. Food and Drug Administra-
tion approval in 2010 for the risk reduction of stroke and systemic
embolism in patients with nonvalvular AF (NVAF). This was quickly
followed by the arrival of drugs that directly inhibit FXa (apixaban,
rivaroxaban, and edoxaban),which is 1 step proximal to the action of di-
rect FIIa inhibitors such as dabigatran in the clotting cascade. Data from
phase 3 clinical trials in patients with NVAF demonstrated that these 4
DOACswere either noninferior or superior towarfarin in terms of efﬁca-
cy (ie, reducing the rates of stroke and systemic embolism) [15-18], and
showed equivalence or improved safety (ie, major hemorrhage and
clinically relevant nonmajor hemorrhage) vs warfarin [15-18]. DOACs
were associated with an approximately 30%-70% reduction in the rates
of ICH vs warfarin [15-18], although theywere associated with general-
ly higher rates of GI bleeding (not further deﬁned; annualized rate
ranged from approximately 0.8% to 3.2% for DOACs [depending on the
agent and dose] vs approximately 1.0% to 2.2% for warfarin)
[15,16,18]. DOACs are also approved for the treatment and prevention
of venous thromboembolism (VTE), for which they were noninferior
to conventional therapy in terms of efﬁcacy outcomes, and showed
equivalence or improvement in the overall safety proﬁle [19-22].
To date, comparatively few data have been published on restarting
OAC therapy after a major hemorrhage and the data that do exist are al-
most exclusively from patients receiving VKAs, with very few data
concerning DOACs. Furthermore, some expert opinion recommends ap-
proaching the re-initiation of DOACs similarly to restart scenarios with
warfarin [23]. This is reﬂected in the discussion below. This review
aims to summarize the key evidence and provide guidance for clinicians
regarding if and when a patient should be restarted on DOAC therapy
following a major hemorrhage.
1. Intracranial hemorrhage and re-initiation of OACs
Intracranial hemorrhage has a heterogeneous etiology, including
spontaneous ICH (eg, lobar and deep hemispheric hemorrhages,
aneurismal subarachnoid hemorrhages, and bleeding arteriovenous
malformations) and traumatic ICH (eg, extra-axial subdural, epidural
hematomas, traumatic subarachnoid hemorrhages, and intra-axial
hemorrhagic contusions). The risk of ICH recurrence can be related to
etiologic factors. For example, superﬁcial (lobar) hemorrhages are
often caused by cerebral amyloid angiopathy, a condition that affects ce-
rebral arteries and arterioles and increases the risk of hemorrhage, and
is associated with recurrence rates of up to 22% [24]. The incidence of
nontraumatic ICH is approximately 25 per 100,000 personyears [25]. It
has been estimated that there are approximately 67,000 cases of spon-
taneous ICH per year in the United States [26], and anticoagulant-
associated ICH accounts for nearly 20% of those [26]. The 30-day case
fatality rate is as high as 50%, andmost survivors are left with some de-
gree of disability, which is often severe [26].
In cases of OAC-related ICH, the therapeutic dilemma is that stop-
ping anticoagulation increases the risk of cerebral ischemia, while con-
tinuing or restarting treatment after stopping it increases the risk of
recurrent bleeding [24]. his has been referred to as “steering between
Scylla and Charybdis,” meaning to have to choose between 2 evils
[24]. The published reports described below are all retrospective analy-
ses of OAC-related ICH, with varying patient populations (eg, some
studies focus on patients with NVAF or patients with mechanical heart
valves, while other studies include patients treated for VTE). It should
be noted that DOACs are not approved for use in patients with mechan-
ical heart valves.A recent report from a German multicenter, retrospective study
(2006-2012) assessed the effects of OAC resumption in patients
with anticoagulation-related (VKAs) spontaneous ICH [27]. Of the
1176 patients with data available, 719 patients were part of the
OAC resumption analysis (the remainder were analyzed for hemato-
ma enlargement [n = 853] or longterm outcomes [n = 1083]). OAC
was restarted in 172 of 719 (23.9%) patients (including 34/50 [68.0%]
with mechanical heart valves, and 110/566 [19.4%] with AF) [27].
Median time to OAC resumption was 31 days (interquartile range
[IQR] 18-65). Restarting OAC therapy was associated with fewer ische-
mic events (OAC 9/172 [5.2%]; no OAC 82/547 [15.0%]; P b .001), and no
signiﬁcant increase in hemorrhagic complications (OAC 14/172 [8.1%];
no OAC 36/547 [6.6%]; P = .48) (Figure) [27]. Furthermore, there was
a decrease in long-term mortality in the subgroup of patients with AF
Table 1
Major Guideline Recommendations on Re-Initiation of OAC Following a Major Bleed
Guideline and Citation Recommendation
European Stroke Organisation (ESO)
guidelines for the management of
spontaneous intracerebral
hemorrhage, 2014 [50]
Recommendation 18: Unable to make
ﬁrm recommendations about whether
and when to resume antithrombotic
drugs after ICH in the absence of RCTs to
address treatment dilemmas
Additional information: Suggested
timings for restarting these drugs range
from not earlier than 14 days up to 30
weeks (data from observational studies)
[30,31]
Guidelines for the management of
spontaneous intracerebral
hemorrhage (American Heart
Association/American Stroke
Association), 2015 [51]
Prevention of Recurrent ICH,
Recommendation 6: Optimal timing to
resume OAC after OAC-related ICH is
uncertain. Avoidance of OAC for at least
4 weeks, in patients without mechanical
heart valves, might decrease the risk of
ICH recurrence. If indicated, aspirin
monotherapy can probably be restarted
in the days after ICH, although the
optimal timing is uncertain
Antithrombotic and thrombolytic
therapy for ischemic stroke,
(Antithrombotic Therapy and
Prevention of Thrombosis, 9th ed:
American College of Chest
Physicians), 2012 [52]
Recommendation 4.3: In patients with a
history of a symptomatic primary ICH,
we suggest against the long-term use of
antithrombotic therapy for the
prevention of ischemic stroke
Remarks: Patients with a history of ICH
who might beneﬁt from antithrombotic
therapy are those at relatively low risk
of recurrent ICH (eg, with deep
hemorrhages) and relatively high risk
(N7% per year) of cardiac
thromboembolic events (eg, with
mechanical heart valves or CHADS2⁎
score of ≥4 points)
ICH= intracranial hemorrhage; OAC= oral anticoagulant; RCT= randomized controlled
trial.
⁎ CHADS2, (score for atrial ﬁbrillation stroke risk) congestive heart failure history, hy-
pertension history, age ≥75 years, diabetes mellitus history, stroke or transient ischemic
attack previously (see also Table 2).
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[HR] 0.258; 95% conﬁdence interval [CI], 0.125-0.534; P b .001).27
Another study linked 3 large Danish registries (1997-2013), and
assessed the risk of recurrent stroke and mortality when restarting
OAC in patients with AF and OAC-associated ICH (n = 1752) [28]. The
majority of patients received VKA (65%) or VKA plus antiplatelet thera-
py (33%), and a small proportion received DOACs (2%) or DOACs plus
antiplatelet therapy (b1%). The overall event rates (using 1 year of
follow-up) of the combined end point of ischemic stroke/systemic em-
bolism and all-cause mortality (per 100 person-years) for patients
treated with OAC was 13.6 vs 27.3 for nontreated patients (HR 0.55;
95% CI, 0.39-0.78; no P-value stated) [28]. Of patients who resumed
OAC treatment after ICH (n = 621), the overall median time from ICH
to the ﬁrst claimed prescription was 34 days [28].
A Canadian registry study of 284 spontaneous warfarinrelated ICH
(intracerebral or subarachnoid hemorrhage) cases, in which warfarin
was restarted in 91 (32%) patients, reported that there was no increase
in 30-day mortality (adjusted odds ratio 0.49; 95% CI, 0.26-0.93; P =
.03) in patients who restarted warfarin [29]. This trend continued at 1
year but was no longer signiﬁcant (adjusted odds ratio 0.79; 95% CI,
0.43-1.43;P = .43) [29]. This study includedVTEindications and valve
prosthesis for OAC therapy, in addition to AF.
A retrospective, 3-center analysis of 234 patients with warfarin-
associated ICH found a 5-fold increased risk of recurrent ICHwith the re-
sumption of OAC in the immediate period (median time: 5.6weeks; IQR
2.6-17) after the index event (HR 5.6; 95% CI, 1.8-17.2; P= .0029), and
the HR for ischemic stroke was 0.11 (95% CI, 0.014-0.87; P= .036) [30].
The combined risk of recurrent ICH and ischemic stroke reached itslowest point if OAC therapy was restarted between 10 and 30 weeks
after the index event [30].
A further report, in which 7 clinical experts assessed scenarios
concerning acute reversal and resumption of OAC in the setting of
warfarin-associated ICH, revealed that expert opinion favored OAC re-
sumption within 3-10 days of ICH if the patient was stable and
anticoagulation was mandatory [31]. A shorter time to restarting OAC
therapy, as early as 72 hours post-bleed, was also recommended in a re-
view of 63 publications that described 492 patients with warfarin-
associated central nervous system hemorrhage (including spinal hem-
orrhage) [32].
Lastly, a retrospective review (1976-1999) of 141 patients with ICH
at high thromboembolic risk (OAC indications: mechanical heart valve,
AF, and prior stroke) found that discontinuation of warfarin for 1-2
weeks (median time not receiving warfarin 10 days; range 0-30 days)
had a comparatively low probability of embolic events, and there was
no recurrence of ICH at 30 days for the 35 patients who were restarted
on OAC [33].2. Gastrointestinal hemorrhage and re-initiation of OACs
Gastrointestinal bleeding also has a diverse etiology (eg, hemorrhag-
ic gastritis, peptic ulcer disease, arteriovenous malformations, and di-
verticulosis), but has generally been studied as a single cohort. Again,
etiology plays a role in recurrence risk, but it is difﬁcult to parse out.
Acute GI bleeds related to both VKA34 and DOAC [18] therapy are
more common in the upper GI tract. Data from an open cohort study
(upper GI bleed n = 21,641) gave an age-standardized incidence rate
(per 1000 person-years) for upper GI tract bleeding of 5.8 in those pre-
scribed warfarin and 2.7 in those prescribed DOACs [34]. A meta-
analysis of data from 11 phase 3 randomized controlled trials reported
no signiﬁcant difference in the overall incidence of major GI bleeding
between DOACs and VKAs (relative risk 0.94; P= .62) [35]. There is ev-
idence, someof it prospective, that restartingOAC therapy after GI hem-
orrhage is beneﬁcial.
A prospective observational study in theUnited States identiﬁed 197
patients who developed GI bleeding while receiving systemic
anticoagulation (145/197 [74%] received warfarin), of whom 76 (39%)
discontinued anticoagulation upon hospital discharge (ie, interruption
of anticoagulation for ≥72 hours after discharge) [36]. Restarting OAC
therapy at hospital discharge was associated with a lower risk of
major thrombotic episodes within 90 days (HR 0.121; 95% CI, 0.006-
0.812; P= .03), and no signiﬁcant difference in mortality was observed
(at 90 days, HR 0.632; 95% CI, 0.216-1.89; P = .40) [36]. Furthermore,
restarting OAC was not signiﬁcantly associated with an increased
risk of recurrent GI bleeding at 90 days (HR 2.17; 95% CI, 0.861-6.67;
P= .10) [36].
A retrospective United States cohort study enrolled patients with AF
who developed GI bleedingwhile receiving anticoagulation (n= 1329)
[37]. Warfarin was restarted in 653 (49%) patients, after a median dura-
tion of 50 days (IQR 21-78). Restartingwarfarin was associated with re-
duced mortality (adjusted HR 0.67; 95% CI, 0.56-0.81; P b .0001) and
decreased risk of thromboembolism (adjusted HR 0.71; 95% CI, 0.54-
0.93; P = .01), but not recurrent GI bleeding (adjusted HR 1.18; 95%
CI, 0.94-1.10; P= .47) [37]. When the outcomes were stratiﬁed by du-
ration of warfarin interruption, restarting warfarin after 7 days was
not associated with increased risk of GI bleeding, but was associated
with decreased risk of mortality and thromboembolism compared
with resuming after 30 days of interruption [37]. These data are in
agreement with other studies [36,38]. These ﬁndings were extended
in a recent meta-analysis that included this study from the United
States, and concluded that the resumption of warfarin following inter-
ruption because of GI bleeding is associated with a reduction in throm-
boembolic events and mortality without a statistically signiﬁcant
increase in recurrent GI bleeding [39].
Table 2
Risk Stratiﬁcation Tools for Stroke Risk in Atrial Fibrillation [57]
Tool and Citation Risk Factor⁎ Score Tool Score
(if Stated)
Annual Event
Rate, % (if Stated)
CHADS2 [41] CHADS2 score Adjusted
stroke rate
CHF (recent) 1 0 1.9
Hypertension (history of) 1 1 2.8
Age ≥75 y 1 2 4.0
DM 1 3 5.9
Stroke/TIA 2 4 8.5
5 12.5
(6 = max. score) 6 18.2
CHA2DS2-VASc [54] CHA2DS2-VASc
score
TEE rate
CHF/LV dysfunction 1 0 0
Hypertension 1 1 0.6
Age ≥75 y 2 2 1.6
DM 1 3 3.9
Stroke/TIA/TE 2 4 1.9
Vascular disease (prior MI, PAD, or aortic plaque) 1 5 3.2
Age 65-74 y 1 6 3.6
Sex category (female) 1 7 8.0
8 11.1
(9 = max. score) 9 100
R2CHADS2 [55]
Renal dysfunction (CrCl b60 mL/min) 2
CHF (recent) 1
Hypertension 1
Age ≥75 y 1
DM 1
Stroke/TIA 2
(8 = max. score)
QStroke (QResearch
database Stroke) [56,57]
Age (at entry) y Range, 25-84
Sex Separate models for
male and female
Treated hypertension (diagnosis of hypertension and ≥1 current
prescription for ≥1 antihypertensive agent)
Yes/No
T1DM Yes/No
T2DM Yes/No
AF Yes/No
CHF Yes/No
CHD Yes/No
Self-assigned ethnicity (White/not recorded, Indian, Pakistani, Bangladeshi,
other Asian, Black Caribbean, Black African, Chinese, other/mixed)
9 categories
Townsend Deprivation Score Continuous
Smoking status (nonsmoker, ex-smoker,
light smoker [b10 cigarettes/day],
moderate smoker [10-19 cigarettes/day],
heavy smoker [≥20 cigarettes/day])
5 categories
SBP Continuous
TC:HDL-C ratio Continuous
BMI Continuous
Family history of coronary disease
(in ﬁrst-degree relative age b60 y)
Yes/No
RA Yes/No
CKD Yes/No
Valvular heart disease Yes/No
(99% = max. score)
ATRIA (Anticoagulation and Risk
Factors in Atrial Fibrillation) Stroke
[58]
Prior stroke
Age, y Without With
≥85 6 9
75-84 5 7
65-74 3 7
b65 0 8
Female sex 1 1
DM 1 1
CHF 1 1
Hypertension 1 1
Proteinuria 1 1
eGFR b45 mL/min/1.73 m2 or ESRD 1 1
(12 =
max.
score)
(15 =
max.
score)
AF atrial ﬁbrillation; BMI= bodymass index; CHD= coronary heart disease; CHF= congestive heart failure; CKD= chronic kidney disease; CrCl= creatinine clearance; DM=diabetes
mellitus; eGFR= estimated glomerular ﬁltration rate; ESRD= end-stage renal disease; HDL-C= high-density lipoprotein cholesterol; LV= left ventricular; MI=myocardial infarction;
PAD=peripheral artery disease; RA= rheumatoid arthritis; SBP= systolic blood pressure; T1= type 1 (DM); T2= type 2 (DM); TC= total cholesterol; TE= thromboembolism; TEE=
thromboembolic event; TIA = transient ischemic attack.
⁎ First letter of each row spells out the acronym, unless otherwise stated.
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Table 3
Risk Stratiﬁcation Tools for Bleeding Risk in Atrial Fibrillation [57]
Tool and Citation Risk Factor⁎ Score
HAS-BLED [59] Hypertension (SBP N160 mm Hg) 1
Abnormal renal or liver function 1 or 2
Stroke 1
Bleeding history or predisposition 1
Labile INRs (if on warfarin) 1
Elderly (eg, age N65 y, frail
condition)
1
Drugs (eg, concomitant
antiplatelet or NSAIDs) or alcohol
excess/abuse
1 or 2
(9 =
max.
score)
HEMORR2HAGES [60] Hepatic or renal disease 1
Ethanol abuse 1
Malignancy 1
Older age (N75 y) 1
Reduced platelet count or
function
1
Re-bleeding risk 2
Hypertension (uncontrolled) 1
Anemia 1
Genetic factors (CYP2C9 SNP) 1
Excessive fall risk 1
Stroke 1
(12 =
max.
score)
ATRIA (Anticoagulation and Risk
Factors in Atrial Fibrillation)
bleeding [61]
Anemia 3
Severe renal disease
(eGFR b30 mL/min/1.73 m2 or
dialysis dependent)
3
Age ≥75 y 2
Prior hemorrhage 1
Diagnosed hypertension 1
(10 =
max.
score)
CYP2C9 = cytochrome P450 2C9; eGFR = estimated glomerular ﬁltration rate;
INR = international normalized ratio; NSAIDs = nonsteroidal antiinﬂammatory drugs;
SBP = systolic blood pressure; SNP = single nucleotide polymorphism.
⁎ First letter of each row spells out the acronym, unless otherwise stated.
Table 4
Risk Stratiﬁcation Tools for Predicting Venous Thromboembolism Risk Recurrence [65]
Tool and Citation Risk Factor Score
HERDOO2 (Hyperpigmentation,
Edema, Redness, D-dimer,
Obesity, Older age, 2 scores)
[62]
Clinical decision rule to identify
patients at low risk of recurrent
VTE after 5-7 months of OAC
therapy
Men Always
long-term
AC
Women Long-term
AC if score
≥2
Predictive factors for women Score
Post-thrombotic signs
(hyperpigmentation, edema, or
redness in either leg)
1
D-dimer level ≥250 mg/L
(during anticoagulation)
1
BMI ≥30 kg/m2 1
Age ≥65 years 1
Vienna (Medical University of
Vienna) [63]
Sex
Male 60
Female 0
Site of VTE
Distal DVT 0
Proximal DVT 70
Pulmonary embolism 90
D-dimer levels
Continuous (Low risk of
recurrence with score ≤180)
0-100
DASH (D-dimer level, young Age,
male Sex, and Hormonal
therapy associated with the
index VTE event) [64]
Elevated D-dimer levels 1 month
after stopping VKAs
2
Age b50 y 1
Male sex 1
Women taking oral
contraceptives (Low risk of
recurrence with score ≤1)
−2
AC=anticoagulation; BMI=bodymass index; DVT=deep vein thrombosis; OAC=oral
anticoagulant; VKA = vitamin K antagonist; VTE = venous thromboembolism.
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The overall annual risk of anymajor hemorrhage for patients receiv-
ing OACs is 2% to 3%, with the annual risk of OAC-related ICH at 0.3% to
0.5% [11]. This must, however, be considered against the annual risk of
arterial thromboembolism in the absence of OAC therapy, which is
12% to 22% for patients with mechanical heart valves, and 6% to 18% in
patients with AF plus a CHA2DS2-VASc score of ≥3, and there is a 5% to
7% risk of VTE recurrence in the ﬁrst 3 months for patients receiving
OAC for previous VTE [40-43]. The clinical consequences of a thrombotic
or bleeding event must also be taken into consideration when deciding
to restart OACs. For example, mechanical heart valve thrombosis is fatal
in approximately 12% of patients, embolic stroke results in death in up
to 27% of cases, while VTE has a case-fatality rate of approximately 4%
to 14%, and major bleeding has a case-fatality rate of approximately
9% to 13% [44-49]. Most of the major guidelines, including those from
the American Heart Association/American Stroke Association, the
American College of Chest Physicians, and the European Stroke Organi-
sation, provide advice on whether to restart OAC therapy after major
hemorrhage in appropriately risk stratiﬁed patients, although they dif-
fer over the timing (Table 1) [30,31,50-52]. For example, the American
Heart Association/American Stroke Association guidelines for the man-
agement of spontaneous ICH had previously advised restarting OAC at
≥1week after ICH [53], but recently revised their guidance and now rec-
ommend avoidance of OACs for at least 4weeks in patientswithoutme-
chanical heart valves [51].Evaluation of an individual’s risk factors for stroke, bleeding, and VTE
recurrence is essential to understanding the risks and beneﬁts of OAC
therapy for that individual, and several risk-stratiﬁcation tools are avail-
able (Table 2 [41,54-58], Table 3 [57,59-61], and Table 4 [62-65]). The
CHA2DS2-VASc score [54] to assess stroke risk and the HASBLED score
[59] to assess bleeding risk are the most commonly used tools, as rec-
ommended by the current guidelines [5,6]. The HAS-BLED score was
used to identify modiﬁable risk factors for bleeding [5]. It should be
noted that these schemes were developed in populations with AF and
did not include patients with VTE. The same is true of the HEMOR-
R2HAGES score for bleeding risk [60], whereas the Outpatient Bleeding
Risk Index (OBRI) validation did include patients with VTE [66]. Validat-
ed scores for predicting VTE recurrence include HERDOO2 [62], the Vi-
enna model [63], and DASH [64]. Unfortunately, bleeding scores
(OBRI, HEMORR2HAGES, HAS-BLED, and ATRIA [61]) have shown
poor discriminatory ability to predict major bleeding and clinically rele-
vant nonmajor bleeding in subsequent external validation studies [67].
A broad clinical assessment must be performed following an OAC-
related major hemorrhage, including identiﬁcation of the underlying
reason forwhich the patient originally received anticoagulation therapy
and their risk of stroke or VTE and bleeding. Factors that would favor
restarting OAC therapy include the presence of deep ICH, a mechanical
heart valve, secondary prevention, or high risk of stroke or VTE [68]. A
corrected cause of bleeding (eg, a clipped aneurysm or a repaired
aortoenteric ﬁstula) would also facilitate OAC restart. Factors that
would confer an unfavorable beneﬁterisk proﬁle for restarting OAC
therapy include lobar ICH, multiple microbleeds on gradientrecalled-
echo-magnetic resonance imaging (correlating with cerebral amyloid
angiopathy and an increased risk of ICH recurrence), and a low risk of
stroke or VTE [68].
24 T.J. Milling Jr, A.C. Spyropoulos / American Journal of Emergency Medicine 34 (2016) 19–25If a patient is deemed appropriate to restart OAC therapy, the clini-
cianmust decidewhen re-initiation should occur, and how rapidly ther-
apeutic anticoagulation is needed. The decision pathway for re-
initiation of OAC therapy must recognize when the increasing risk of
thromboembolism outweighs the decreasing risk of recurrent hemor-
rhage. Thus, restarting OAC might be considered earlier in patients
with mechanical heart valves or stabilized GI bleeds, later with inpa-
tients with ICH or a low risk of stroke/VTE, and probably disregarded
in cases of lobar ICH or in the presence of intracranial microbleeds. As
evidenced from the studies described, the recommendations varywide-
ly (eg, from 3 days [31] to 30 weeks [30] for ICH), and are based on ret-
rospective data rather than prospective data from randomized,
controlled clinical trials. A recent nonsystematic review of antithrom-
botic treatment and ICH by Hofmeijer et al [24] concluded that OAC
therapy should be resumed after 1-2 weeks in patients with deep ICH
and high risk of cerebral ischemia (ie, patients with NVAF and a
CHA2DS2-VASc score of ≥4 or a mechanical heart valve), but restart
should be later (ie, after 4 weeks) in other patients. A further consider-
ation when re-initiating OAC therapy is the time to onset of action,
which is much faster for DOACs than for warfarin (0.5-4 hours vs 36-
72 hours, respectively) [69].
Lastly, it should also be noted that the risk of thromboembolism is
still high in the immediate period after a major hemorrhage, and that
rapid reversal of OAC, regardless of the method, can be attended by
thromboembolic events in some patients. A post hoc analysis of throm-
boembolic complications after warfarin reversal, examining data from
388 patients presenting with acute major hemorrhage or in need of ur-
gent surgical intervention, reported that the incidence of thromboem-
bolic events in the ﬁrst 45 days was similar following VKA reversal
with either 4-factor prothrombin complex concentrate or plasma (ap-
proximately 7% for each agent) [70].
4. Conclusions
In summary, the decision to restart OAC therapy in a patient receiv-
ing chronic OACwhohas suffered fromamajor bleed is a highly individ-
ualized assessment. The risk of thromboembolism must be balanced
with the risk of recurrentmajor bleeding in that individual, while taking
into account the morbidity and case-fatality of a thrombotic/bleed out-
come, in addition to the optimal time frame of when to restart OAC. It is
also dependent upon the original indication for OAC, and the type of
major bleed from which the patient suffered. Many patients with
OAC-associated ICHs can restart OAC at some point between 1 and 30
weeks, but careful risk stratiﬁcation must be performed. Most patients
with OAC-associated clinically stable GI hemorrhages can restart OAC
at 1 week post index bleed. Currently, there are few data on how
DOACs might change the risk–beneﬁt analysis of when to restart thera-
py after a major bleed event, particularly in ICH. However, the available
data are reassuring in that practitioners would expect approximately
50% fewer of these events vs VKA-treated patients, which hasmajor im-
plications from a public health perspective. A larger number of well-
designed studies are needed in this area for both VKA and, especially,
for DOAC-treated patient groups.
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